T cells modified with chimeric antigen receptor are an attractive strategy to treat Epstein-Barr virus (EBV) associated malignancies. The EBV latent membrane protein 1 (LMP1) is a 66-KD integral membrane protein encoded by EBV that consists of transmembrane-spanning loops. Previously, we have identified a functional signal chain variable fragment (scFv) that specifically recognizes LMP1 through phage library screening. Here, we constructed a LMP1 specific chimeric antigen receptor containing anti-LMP1 scFv, the CD28 signalling domain, and the CD3f chain (HELA/CAR). We tested its functional ability to target LMP1 positive nasopharyngeal carcinoma cells. HELA/CAR cells were efficiently generated using lentivirus vector encoding the LMP1-specific chimeric antigen receptor to infect activated human CD3+ T cells. The HELA/CAR T cells displayed LMP1 specific cytolytic action and produced IFN-c and IL-2 in response to nasopharyngeal carcinoma cells overexpressing LMP1. To demonstrate in vivo anti-tumor activity, we tested the HELA/CAR T cells in a xenograft model using an LMP1 overexpressing tumor. Intratumoral injection of anti-LMP1 HELA/CAR-T cells significantly reduced tumor growth in vivo. These results show that targeting LMP1 using HELA/CAR cells could represent an alternative therapeutic approach for patients with EBV-positive cancers.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a malignant epithelial carcinoma of the head and neck region and most commonly seen in southeast Asia, especially in the southern provinces of China [1] . In contrast to other head and neck cancers, Epstein-Barr virus (EBV) infection has been associated with NPC in general and specifically with undifferentiated NPCs. Most NPC patients are first diagnosed with nodal involvement or distal metastasis. Underlying EBV infection may be one contributing factor to the highly metastatic phenotype of NPC [2] .
Latent membrane protein 1 (LMP1) is a 66 KD integral membrane protein in EBV. LMP1 contains three domains: a short cytoplasmic N-terminal, a transmembrane domain with 6 transmembrane-spanning loops and a long cytoplasmic C-terminus [3, 4] . LMP1 is essential for EBV-mediated growth transformation of infected cells. The C-terminus of the protein triggers a variety of signal pathways through three functional domains termed C-terminal activating regions 1-3 (CTAR1, CTAR2 and CTAR3) [5] .
In patients with EBV-associated NPC, adoptive cell therapy with EBV-specific autologous cytotoxic T lymphocytes (CTLs) can control disease progression. In these studies, the adoptively transferred CTLs showed significant antitumor activity and were safe for patients [6] [7] [8] [9] [10] . However, the efficacy of in vitro induction of EBV-specific T cell responses is low. Chimeric antigen receptor (CAR) modified T cell therapy combines the advantages of T cell based therapy and antibody based tumor specificity. In this approach, T cells are genetically modified to recognize tumor-associated antigens (TAAs). The two most common approaches are: 1) expression of TCR variable a and b chains that are derived from tumor-specific T cell clones; 2) T cell genetic modification with CARs that specifically recognize tumors through single-chain variable fragments (scFv) cloned from TAA specific antibodies. An additional advantage to using CAR expressing T cells is that they recognize tumor cells in an HLA-unrestricted manner [11] . Previously, we have identified a human Fab fragment, HELA-Fab, that specifically recognizes a polypeptide in the extramembrane domain of LMP-1 [12] . In the current study, we constructed a second generation CAR, based on the HELA-Fab fragment. The second generation CAR, HELA/CAR, consists of the anti-LPM1 scFv, IgG1 CH2CH3, and a CD28/CD3 expression cassette (Lv-anti-LMP1-CH2CH3-CD28-CD3f). In this study we developed a novel approach using CAR modified T cells targeting the LMP-1 protein to improve EBV-targeted T cell therapy.
MATERIALS AND METHODS

Construction of the HELA/CAR recombinant lentiviral vector
The CAR HELA/CAR contains genetic elements coding the anti-LMP1 scFv, human IgG1 CH2CH3 domain (CH2CH3) and a CD28-CD3f expression cassette. The anti-LMP1 scFv was derived from HELAFab, which has the ability to bind to LMP1 extramembrane domain (EMD) (12) . The DNA sequence for the anti-LMP1 scFv moiety was optimized and synthesized by Genescript. The optimized sequence contained a heavy chain variable region-(GGGS) 3 -a light chain variable region sequence. The fragment encoding the anti-LMP1 scFv, CH2CH3, and CD28-CD3f was generated by polymerase chain reaction (PCR) using the following primers: F: CGGAATTCCCATGGAT-TGGATTTGGAGG; R: GCTCTAGAGCATGCTT-AGCGAGGGGGC and cloned into EcoRI and XbaI sites of the lentiviral vector pLVX-IRES-ZsGreen (Clontech, USA). The new vector was verified by DNA sequencing.
Lentivirus production
To produce lentivirus stocks, the HELA/CAR plasmid described above was transfected into X-293T cells (Clontech) with pMD2.G and psPAX2 using 293fectin T M Transfection Reagent (Invitrogen, Carlsbad, CA, USA). The supernatants harvested from the transfected cells containing the lentivirus particles were filtered and concentrated by ultracentrifugation (Amicon Ultra 100 kD, Millipore, USA). The supernatant lentivirus titers were determined by Lenti-X GoStix (Clontech). The supernatant was snap frozen in liquid nitrogen and stored at -80 uC.
Lentivirus transduction
Non-tissue culture treated 24 well plates (BD Biosciences, USA) were coated with 0.5 mL RetroNectin (20 mg/mL) in PBS for 2 hours at room temperature (RT). The RetroNectin solution was aspirated and the wells were blocked with 0.5 mL Hanks9 balanced salt solution (HBSS) plus 2% bovine serum albumin (BSA) for 30 minutes at room temperature. The blocking solution was aspirated and the wells were washed with HBSS plus 2.5% HEPES. 0.1 mL of HELA/CAR and control lentiviral supernatants were thawed, diluted rapidly and added to each RetroNectin-coated well. The plates were centrifuged at 3800 rpm for 2 hours at 32 uC (13) . The virus-containing supernatant was aspirated from wells. Blood samples were obtained from healthy donors under pro-LMP1-targeting T cells suppress nasopharyngeal carcinoma cell growthtocols approved by Jiangsu Province Blood Center. PBMCs were isolated by Ficoll density gradient separation. Subsequently, PBMCs were activated with anti-CD3 (OKT3) and anti-CD28 antibodies-coated plates for 3 days without IL-2. The HELA/CAR lentivirus coated wells were seeded with 1610 6 activated T cells at a concentration of 0.5610 6 cell/mL in T cell medium (GT-T551, Takara, Japan) plus 100 U/mL of IL-2. After the T cells were added to each well, they were centrifuged at 1000 g for 10 minutes at 32 uC. The plates were incubated at 37 uC overnight. The transduction was repeated the next day.
Expression of LMP1-CAR on CAR T cells
T cells expressing HELA/CAR were detected by flow cytometry using the ZsGreen fluorescent protein encoded by the lentivirus vector. The percentage of T cells positive for ZsGreen fluorescent protein indicated lentivirus transfection efficiency. Western blot was used to verify HELA/CAR protein expression in T cells. T cells transduced with control lentivirus or lentiviral HELA/CAR were lysed in 100 mL RIPA buffer. After centrifugation, the samples were denatured and electrophoresed by 10% SDS-PAGE. The samples were transferred to a PVDF membrane (Bio-Rad, USA) and immunoblotted with mouse anti-human CD3f antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blot was incubated with horseradish peroxidase conjugated goat anti-mouse IgG (Jackson ImmunoResearch, USA) and detected by the ECL Western blot analysis system (Bio-Rad).
Cytotoxicity assay
A slightly modified version of a previously published flow cytometry cytotoxicity assay was used [14] . In this assay, NPC cells SUNE1 (LMP1 negative) or SUNE1-LMP1 (LMP1 positive) were labelled at 1610 6 6 cells/mL in T cell medium in the absence of IL-2, were combined with target cells. The assay was performed in triplicate. The plates were incubated at 37 uC for 24 hours. The supernatant concentration of IFN-c was determined by ELISA according to the manufacturer9 s instructions (eBioscience).
Intracellular cytokine staining assay
T cells were labelled with CFSE (final concentration of 1 mM) using a standard protocol [15] and mixed with SUNE1-LMP1 and SUNE1 cells separately at a 5:1 ratio and incubated at 37 uC for 2 hours. 1 mg/mL of brefeldin A (eBioscience) was added, and cells were incubated for additional 2 hours. Subsequently, the cells were permeabilized, and intracellular staining was conducted for IFN-c and IL-2 according to the instructions of staining of intracellular antigens for flow cytometry (eBioscience). Data acquisition was performed with a BD FACSCalibur (BD Biosciences), and analysis was performed with CFSE gate.
Mouse xenograft model
On day 0, 6-week-old male BALB/c nude mice (SLAC Laboratory) were subcutaneously injected with 5610 6 SUNE1-LMP1 cells. When the tumor burden reached about 100 mm 3 approximately 10 days after tumor cell inoculation, the mice were randomly assigned to three different groups (N 5 5/group). The animals were percutaneously intratumorally injected with 5 6 10 6 T cells/100 mL on day 10, 20, 30, and 40. Group A received HELA/CAR T cells, Group B received control lentivirus transfected cells and Group C received normal saline (NS). Tumor growth was monitored by calliper measurement, and tumor volume was calculated using the formula: 1/2 6 length 6 (width) 2 . This study was carried out in strict accordance with the institutional and state guidelines for the care and use of laboratory animals.
Statistical analysis
ANOVA was used to identify difference among treatment groups. Once a significant difference was confirmed, Student9 s t test was used to calculate the significance of difference between two treatment groups (P value). A P value less than 0.05 was considered statistically significant.
RESULTS
Construction of HELA/CAR
The HELA/CAR construct is shown in Figure 1A . The HELA/CAR vector encodes the anti-LMP1 scFv, IgG1 CH2CH3, a transmembrane domain of CD28 (amino acids 93-136), the cytoplasmic component of CD3f chain (amino acids 52-163), and a lentiviral backbone. The anti-LMP1 scFv CD3 + T cells were transduced using lentiviral HELA/CAR at 5610 6 U/ mL. Five to 7 days after the stimulation, the cultures were almost 100% CD3 + T cells ( Fig. 1B; left panel) . The CD3 + T cells were 72-79% CD8 + T cells and 14-17% CD4 + T cells ( Figure 1B ; right panel). Infection with lentivirus at a multiplicity of infection of 30-40 was performed on day 3 in the presence of 100 U/mL recombinant human IL-2. The transduction efficiency was measured by flow cytometric analysis of the ZsGreen positive population. As show in Fig. 1C (left panel) , the transduction efficiency was 68-85%. Surface expression of HELA/CAR was confirmed using anti-human Fc-Cy3. The percentage of FC-Cy3+T cells was 72-84% ( (Fig. 1D) .
Cytotoxicity of HELA/CAR T cells against LMP1 expressing NPC cells in vitro
To assess the functionality of the HELA/CAR T cells, we investigated whether they could recognize and kill LMP1 expressing NPC cells. LMP1 positive and negative SUNE1 cells were labelled with eFlour670 and used as target cells to determine the cytotoxic potential of transfected T cells. Neither ZsGreen T cells nor non-transfected T cells effectively killed the LMP1 positive target cells (Fig. 2A) . In contrast, the HELA/CAR T cells killed a significantly higher percentage of target cells at each effect:target ratio (P , 0.05). (Fig. 2A) . None of the T cells killed the LMP1 negative SUNE cells (Fig. 2B) . Thus, the HELA/CAR T cells display specific and efficient targeting of LMP1 positive NPC cells.
HELA/CAR T cells produced IL-2 and IFN-c in a LMP1 specific manner
We investigated the functional cytokine response of HELA/CAR T cells to LMP1+ SUNE cells. The transfected T cells and target cells were co-cultured for 24 hours at a 1:1 ratio. IFN-c levels were detected in the supernatants by ELISA. HELA/CAR T cells, but not ZsGreen T cells and non-transfected T cells were activated and secreted IFN-c when co-cultured with LMP1 expressing NPC cells (Fig. 3A) . Co-culture with LMP1 negative SUNE cells did not induce IFN-c release (Fig. 3A) .
We demonstrated LMP1-specific cytokine production by HELA/CAR T cells by intracellular cytokine staining ( Fig. 3B and 3C) . Approximately 48% and 34% of the HELA/CAR T cells produced IL-2 and IFN-c when co-cultured with LMP1 expressing SUNE1 cells. However, only 2% and 5% of the nontransduced T cells co-cultured with LMP1-SUNE1 cells produced IL-2 and IFN-c, respectively. In addition, only 6% and 17% of ZsGreen transduced T cells produced IL-2 and IFN-c, respectively (Fig. 3B) . Data from 3 different experiments confirmed that the differences in cytokine production between the experimental and control groups were significant (P , 0.05).Thus, in general, more HELA/CAR T cells than control effector cells (ZsGreen and non-transfected T cells) produced cytokine in response to LMP1+ NPC tumor cells.
HELA/CAR T cells inhibited the growth of LMP1 expressing NPC cells in a subcutaneous xenograft model
To evaluate the in vivo antitumor activity of HELA/ CAR T cells, we used a xenograft model. BALB/c nude mice were inoculated with SUNE1-LMP1 cells in the flanks. In this model, the HELA/CAR T cells substantially inhibited the growth of tumors, while control T cells did not. Statistical analysis of the tumor growth curve revealed significant differences between the HELA/CAR and control groups (P , 0.05, Fig. 4) . 
DISCUSSION
Gene transfer to redirect the specificity of T lymphocytes to recognize cancer cells through the expression of a CAR specific for a tumor cell-surface molecule is an active area of cancer research. CAR T cells are able to recognize tumor antigen through specific scFv without MHC restriction. Recent clinical studies have shown that CD19-CAR T cells can eliminate CD19
+ tumor cells in the bone marrow and blood in patients with advanced chronic or acute lymphocytic leukemia (CLL) [16] [17] [18] . These data suggest that CAR T cells are a powerful tool for cancer therapy. However, there are safety concerns associated with using CAR T cells to target TAAs. In a phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, CAR T cells specific for carbonic anhydrase IX (CAIX) damaged the bile duct epithelium due to the expression of the target antigen CAIX on normal tissue [19] . Some toxicity was observed in Her2/neu specific CAR trials. One patient died 5 days after adoptive transfer of HER2-CAR T cells because a large number of HER2-CAR T cells localized to the lung and released cytokines in response to low levels of ERBB2/HER2 on lung epithelial cells [20] . To minimize the risk of toxicity to normal tissue, we selected a virus-specific antigen, LMP1, as the target for therapy. LMP1 is expressed only in virus-infected cells and not in normal cells. Thus, off-target toxicity should be limited in clinical application of HELA/CAR T cells.
Anti-EBV T cells have become powerful therapeutic tools for the treatment of EBV-associated malignancies. Promising early studies used EBV-specific T cells (EBV-CTL) stimulated with EBV-transformed B cells (LCL) to effectively treat post-transplant lymphomas in stem cell transplant patients [21] . However, EBV-CTL therapy for EBV-associated malignancies such as NPC and Hodgkin lymphoma has had only mixed success [22] [23] [24] . Indeed, evidence suggests that EBV-specific T cells expanded by LCL are specific for EBNA3 proteins that are not expressed in NPC cells [25] . To overcome this limitation, more recent approaches have targeted LMP1 in NPC with LMP-specific T cells and have improved the efficacy of current adoptive immunotherapy approaches [26, 27] . LMP1-specific T cells were undetectable in PBMCs from donors, but the HELA/ CAR T cells produced in this study specifically recognized LMP1 positive NPC cells and could be an ideal choice for immunotherapy.
Another concern with using CAR T cells as a therapeutic is that they may be immunogenic in a patient. In vivo immunogenicity of CAR T cells could also affect their persistence post-transfer. If murine Ig VH and VL are used to make the scFv fragments incorporated in the CAR, the mouse domain will induce humoral and cellular immune responses [28] . To prevent this, the HELA/CAR cells use a human anti-LMP1 scFv [12] . Thus the potential for immunogenicity of the HELA/CAR T cells is limited.
First generation CARs featured a single signalling domain (typically CD3f), and were found to have limited clinical activity for several carcinomas [19, 29, 30] . The second generation CARs include a costimulatory domain such as CD28, CD134, CD137, CD244, or ICOS [31] [32] [33] [34] . Incorporating a CD28 domain into a CAR can enhance IL2 production and improve T cell expansion and persistence [35] . The HELA/CAR cells generated here exhibit LMP1 specific recognition of NPC cells in vitro, have efficient killing activity and produce IFN-c and IL-2 in response to LMP1+ tumor cells. Most importantly, these cells were able to control LMP1+ tumor growth in an in vivo model. The results from our studies indicate that the HELA/CAR T cells could warrant further testing in clinical studies for treatment of EBV-positive cancer patients. 
